1. Aly MMOM, Abo-Madyan Y, Jahnke L, Wenz F, Glatting G. Comparison of breast sequential and simultaneous integrated boost using the biologically effective dose volume histogram (BEDVH). Radiation Oncology (London, England) 2016; 11:16.

  2. Bailey DL, Pichler BJ, Guckel B, Barthel H, Beer AJ, Botnar R, Gillies R, Goh V, Gotthardt M, Hicks RJ, Lanzenberger R, la Fougere C, Lentschig M, Nekolla SG, Niederdraenk T, Nikolaou K, Nuyts J, Olego D, Riklund KA, Signore A, Schafers M, Sossi V, Suminski M, Veit-Haibach P, Umutlu L, Wissmeyer M, Beyer T. Combined PET/MRI: from Status Quo to Status Go. Summary Report of the Fifth International Workshop on PET/MR Imaging; February 15-19, 2016; Tubingen, Germany. Molecular Imaging and Biology 2016; 18:637-650.

  3. Beer AJ, Schwarzenbock SM, Zantl N, Souvatzoglou M, Maurer T, Watzlowik P, Kessler H, Wester HJ, Schwaiger M, Krause BJ. Non-invasive assessment of inter-and intrapatient variability of integrin expression in metastasized prostate cancer by PET. Oncotarget 2016; 7:28151-28159.

  4. Crisan D, Treiber N, Kull T, Widschwendter P, Adolph O, Schneider LA. Surgical treatment of melanoma in pregnancy: a practical guideline. Journal Der Deutschen Dermatologischen Gesellschaft 2016; 14:585-593.

  5. D'Alessandria C, Pohle K, Rechenmacher F, Neubauer S, Notni J, Wester HJ, Schwaiger M, Kessler H, Beer AJ. In vivo biokinetic and metabolic characterization of the Ga-68-labelled alpha 5 beta 1-selective peptidomimetic FR366. European Journal of Nuclear Medicine and Molecular Imaging 2016; 43:953-963.

  6. Eiber M, Weirich G, Holzapfel K, Souvatzoglou M, Haller B, Rauscher I, Beer AJ, Wester HJ, Gschwend J, Schwaiger M, Maurer T. Simultaneous Ga-68-PSMA HBED-CC PET/MRI Improves the Localization of Primary Prostate Cancer. European Urology 2016; 70:829-836.

  7. Fabritius G, Brix G, Nekolla E, Klein S, Popp HD, Meyer M, Glatting G, Hagelstein C, Hofmann WK, Schoenberg SO, Henzler T. Cumulative radiation exposure from imaging procedures and associated lifetime cancer risk for patients with lymphoma. Scientific Reports 2016; 6:35181.

  8. Graeter T, Kratzer W, Oeztuerk S, Haenle MM, Mason RA, Hillenbrand A, Kull T, Barth TF, Kern P, Gruener B. Proposal of a computed tomography classification for hepatic alveolar echinococcosis. World Journal of Gastroenterology 2016; 22:3621-3631.

  9. Hardiansyah D, Begum NJ, Kletting P, Mottaghy FM, Glatting G. Sensitivity Analysis of a Physiologically Based Pharmacokinetic Model Used for Treatment Planning in Peptide Receptor Radionuclide Therapy. Cancer Biotherapy and Radiopharmaceuticals 2016; 31:217-224.

  10. Hardiansyah D, Guo W, Kletting P, Mottaghy FM, Glatting G. Time-integrated activity coefficient estimation for radionuclide therapy using PET and a pharmacokinetic model: A simulation study on the effect of sampling schedule and noise. Medical Physics 2016; 43:5145-5154.

  11. Hardiansyah D, Maass C, Attarwala AA, Muller B, Kletting P, Mottaghy FM, Glatting G. The role of patient-based treatment planning in peptide receptor radionuclide therapy. European Journal of Nuclear Medicine and Molecular Imaging 2016; 43:871-880.

  12. Kegel S, Chacon-Caldera J, Tsagogiorgas C, Theisinger B, Glatting G, Schad LR. 19F Oximetry with semifluorinated alkanes. Artificial Cells, Nanomedicine, and Biotechnology 2016; 44:1861-1866.

  13. Kirschner S, Mürle B, Felix M, Arns A, Groden C, Wenz F, Hug A, Glatting G, Kramer M, Giordano FA, Brockmann MA. Imaging of Orthotopic Glioblastoma Xenografts in Mice Using a Clinical CT Scanner: Comparison with Micro-CT and Histology. PLoS One 2016; 11:e0165994.

  14. Kletting P, Kull T, Maass C, Malik N, Luster M, Beer AJ, Glatting G. Optimized Peptide Amount and Activity for Y-90-Labeled DOTATATE Therapy. Journal of Nuclear Medicine 2016; 57:503-508.

  15. Kletting P, Schuchardt C, Kulkarni HR, Shahinfar M, Singh A, Glatting G, Baum RP, Beer AJ. Investigating the Effect of Ligand Amount and Injected Therapeutic Activity: A Simulation Study for Lu-177-Labeled PSMA-Targeting Peptides. Plos One 2016; 11.

  16. Kübler J, Kirschner S, Hartmann L, Welzel G, Engelhardt M, Herskind C, Veldwijk MR, Schultz C, Felix M, Glatting G, Maier P, Wenz F, Brockmann MA, Giordano FA. The HIV-derived protein Vpr(52-96) has anti-glioma activity in vitro and in vivo. Oncotarget 2016; 7:45500-45512.

  17. Leuzy A, Chiotis K, Hasselbalch SG, Rinne JO, de Mendonca A, Otto M, Lleo A, Castelo-Branco M, Santana I, Johansson J, Anderl-Straub S, von Arnim CAF, Beer A, Blesa R, Fortea J, Herukka SK, Portelius E, Pannee J, Zetterberg H, Blennow K, Nordberg A. Pittsburgh compound B imaging and cerebrospinal fluid amyloid-beta in a multicentre European memory clinic study. Brain 2016; 139:2540-2553.

  18. Maass C, Sachs JP, Hardiansyah D, Mottaghy FM, Kletting P, Glatting G. Dependence of treatment planning accuracy in peptide receptor radionuclide therapy on the sampling schedule. Ejnmmi Research 2016; 6.

  19. Maass C, Rivas JR, Attarwala AA, Hardiansyah D, Niedermoser S, Litau S, Wangler C, Wangler B, Glatting G. Physiologically based pharmacokinetic modeling of (18)F-SiFAlin-Asp3-PEG1-TATE in AR42J tumor bearing mice. Nucl Med Biol 2016; 43:243-246.

  20. Maurer T, Gschwend JE, Rauscher I, Souvatzoglou M, Haller B, Weirich G, Wester HJ, Heck M, Kubler H, Beer AJ, Schwaiger M, Eiber M. Diagnostic Efficacy of (68)Gallium-PSMA Positron Emission Tomography Compared to Conventional Imaging for Lymph Node Staging of 130 Consecutive Patients with Intermediate to High Risk Prostate Cancer. Journal of Urology 2016; 195:1436-1442.

  21. Rauscher I, Maurer T, Beer AJ, Graner FP, Haller B, Weirich G, Doherty A, Gschwend JE, Schwaiger M, Eiber M. Value of Ga-68-PSMA HBED-CC PET for the Assessment of Lymph Node Metastases in Prostate Cancer Patients with Biochemical Recurrence: Comparison with Histopathology After Salvage Lymphadenectomy. Journal of Nuclear Medicine 2016; 57:1713-1719.

  22. Rauscher I, Maurer T, Souvatzoglou M, Beer AJ, Vag T, Wirtz M, Weirich G, Wester HJ, Gschwend JE, Schwaiger M, Schottelius M, Eiber M. Intrapatient Comparison of In-111-PSMA I&T SPECT/CT and Hybrid Ga-68-HBED-CC PSMA PET in Patients With Early Recurrent Prostate Cancer. Clinical Nuclear Medicine 2016; 41:E397-E402.

  23. Taouli B, Beer AJ, Chenevert T, Collins D, Lehman C, Matos C, Padhani AR, Rosenkrantz AB, Shukla-Dave A, Sigmund E, Tanenbaum L, Thoeny H, Thomassin-Naggara I, Barbieri S, Corcuera-Solano I, Orton M, Partridge SC, Koh DM. Diffusion-weighted imaging outside the brain: Consensus statement from an ISMRM-sponsored workshop. Journal of Magnetic Resonance Imaging 2016; 44:521-540.

  24. Trajkovic-Arsic M, Heid I, Steiger K, Gupta A, Fingerle A, Worner C, Teichmann N, Wenzel P, Herner A, Steingotter A, Beer A, Schweiger M, Settles M, Haller B, Esposito I, Rummeny E, Schmid RM, Braren R, Siveke JT. Use of Diffusion-weighted magnetic resonance imaging for therapy response evaluation in pancreatic cancer. Oncology Research and Treatment 2016; 39:113-114.

  25. Trebeschi S, Riederer I, Preibisch C, Bohn KP, Forster S, Alexopoulos P, Zimmer C, Kirschke JS, Valentinitsch A. Diagnostic Potential of Pulsed Arterial Spin Labeling in Alzheimer's Disease. Frontiers in Neuroscience 2016; 10.

  26. Widschwendter P, DeGregorio N, Beer A, Ebner F, Kull T, Janni W, Scholz C. Sentinel lymph nodes in gynecological malignancies. Onkologe 2016; 22:999-1010.